Psychics predict ‘nothing good’ for 2025 — expect a ‘deeply transformative phase’ By Reda Wigle Published Dec. 25, 2024, 7:34 a.m. ET ...

Kashiv Biosciences, LLC, a global leader in biopharmaceutical innovation, today announced that their abatacept biosimilar candidate, KSHB002, has succ ...

In the current ongoing phase 3 trial, we found evidence for the superiority of semaglutide over placebo for histologic reductions in steatohepatitis and fibrosis.

Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta–selective agonist in ...